Browse
Submit Data
Databases
API
Help

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PPARγ agonists promote the resolution of myelofibrosis in preclinical models.

ABSTRACT: Myelofibrosis (MF) is a non-BCR-ABL myeloproliferative neoplasm associated with poor outcomes. Current treatment has little effect on the natural history of the disease. MF results from complex interactions between (a) the malignant clone, (b) an inflammatory context, and (c) remodeling of the bone marrow (BM) microenvironment. Each of these points is a potential target of PPARγ activation. Here, we demonstrated the therapeutic potential of PPARγ agonists in resolving MF in 3 mouse models. We showed that PPARγ agonists reduce myeloproliferation, modulate inflammation, and protect the BM stroma in vitro and ex vivo. Activation of PPARγ constitutes a relevant therapeutic target in MF, and our data support the possibility of using PPARγ agonists in clinical practice.

SUBMITTER: Lambert J

PROVIDER: S-EPMC8159700 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

PPAR-y agonists promote the resolution of myelofibrosis in preclinical models

Project description:PPAR-g abrogates TGF-β1 signaling by trapping the p300 co-factor in BM stromal cells

2021-04-16 | GSE141378 | GEO

PPAR-y agonists promote the resolution of myelofibrosis in preclinical models

Project description:PPAR-y agonists promote the resolution of myelofibrosis in preclinical models

| PRJNA593237 | ENA

PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity.

Project description: Not available

| S-EPMC5308629 | biostudies-literature

Androgen receptor agonists increase muscle mass and function in preclinical models of DMD

Project description:Mdx mice were castrated and treated with selective androgen receptor modulator (SARM) GTx-026. Ten weeks after treatment, gastrocnemious muscle were isolated, RNA extracted, and sequenced using ion torrent sequencer.

2017-05-12 | GSE98473 | GEO

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.

Project description: Not available

| S-EPMC8704992 | biostudies-literature

PPARγ agonists delay age-associated metabolic disease and extend longevity.

Project description: Not available

| S-EPMC7681041 | biostudies-literature

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.

Project description: Not available

| S-EPMC6109362 | biostudies-literature

Amorfrutins are selective PPARγ agonists with potent antidiabetic properties

Project description:Faced by an alarming incidence of metabolic diseases including obesity and type 2 diabetes worldwide, there is an urgent need for effective strategies for preventing and treating these common diseases. The nuclear receptor PPARγ (peroxisome proliferator-activated receptor gamma) plays a crucial role in metabolism. We isolated the amorfrutins from edible parts of the plants Glychyrrhiza foetida and Amorpha fruticosa, and identified these natural products as a new chemical class to treat insulin resistance and diabetes by selectively activating PPARγ. In contrast to existing synthetic PPARγ drugs, the amorfrutins display unique properties by separating insulin sensitization from unwanted side effects. In obese mouse models, amorfrutin treatment significantly improved important metabolic and inflammatory parameters. In summary, PPARγ activation by selective amorfrutins derived from edible biomaterial is a promising approach to combat metabolic diseases and other diseases in which PPARγ is involved in.

2012-05-02 | GSE28384 | GEO

PPARα and PPARγ activation is associated with pleural mesothelioma invasion, but therapeutic inhibition is ineffective in preclinical models

Project description:Mesothelioma is a cancer that typically originates in the pleura of the lungs. It rapidly invades the surrounding tissues, resulting in pain and shortness of breath. We compared mesothelioma cell lines that were injected either subcutaneously or intrapleurally and found that only the latter resulted in invasive and rapid growth. Pleural tumours displayed a transcriptional signature consistent with increased activity of nuclear receptorsPPARα and PPARγ and with an increased abundance of endogenous PPAR-activating ligands. We found that chemical probe GW6471 is a potent dual PPARα/γ antagonist with anti-invasive and anti-proliferative activity in vitro. However, administration of GW6471 at doses that provided sustained plasma exposure levels sufficient for inhibition of PPARα/γ transcriptional activity did not result in significant anti-mesothelioma activity in mice. Lastly, we demonstrate that the in vitro antitumour effect of GW6471 is off-target. We conclude that dual PPARα/γ antagonism alone is not a viable treatment modality for mesothelioma.

2021-11-14 | GSE180618 | GEO

Resolution phase lipid mediators of inflammation: agonists of resolution.

Project description: Not available

| S-EPMC3732499 | biostudies-literature